The PDE10A Inhibitor TAK-063 Reverses Sound-Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome (February, 10.1007/s13311-021-01005-w, 2021)

Summary: This study demonstrates the beneficial effects of the PDE10A inhibitor TAK-063 on normalizing EEG biomarkers in a mouse model of Fragile X syndrome, suggesting potential for further translational treatment development without noticeable side effects.